Pfizer has announced a revised profit estimate for 2025, underpinned by a cost-cutting program, amid falling COVID product revenues and patent expirations. Shares rose 3.7% after the company reported a better-than-expected quarterly profit. However, Pfizer remains cautious, maintaining annual sales forecasts of between $61 billion and $64 billion, due to pandemic uncertainties and political pressure to cut drug prices.
Sources
Pfizer își majorează estimarea de profit pentru 2025, pe fondul reducerilor masive de costuri și al presiunilor politice din partea lui Trump
Pfizer își ridică prognoza de profit pentru 2025, mizând pe reduceri agresive de costuri și negocieri
Pfizer îşi majorează estimarea de profit pentru 2025, pe fondul reducerilor masive de costuri şi al presiunilor politice din partea lui Trump
Pfizer îşi majorează estimarea de profit pentru 2025, pe fondul reducerilor masive de costuri şi al presiunilor politice din partea lui Trump
Latest News
15:27
A national operational center in the energy sector will be created to manage the energy crisis / Ilie Bolojan: "Citizens will not be limited or disconnected"
15:25
The government approved three memorandums for the filling of 402 vacant positions in Transgaz, Transelectrica, and Hidroelectrica, necessary for the security of the national energy system.
15:14
Users who purchase road tax online may incur significant additional fees. CNAIR recommends purchasing only from the official portal.
15:03
The police in Covasna discovered 130 cannabis plants following a raid in the village of Dalnic.
14:53
The government has adopted the Risk Preparedness Plan in the field of electricity, allowing Transelectrica to limit the consumption of large companies.
See more news